NEW YORK (GenomeWeb) – Abbott today said that its Diagnostics business grew sales 5 percent year over year in the third quarter, driven in part by strong growth in its core laboratory and point-of-care tests.

For the three months ended September 30, Abbott reported overall revenues of $6.83 billion, up 29 percent on a reported basis and up 6 percent on a comparable operational basis from $5.30 billion in Q3 2016. The company beat the consensus Wall Street estimate of $6.72 billion.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.